Isma Benattia, M.D., MBA, currently serves as the Head of Medical for the European headquarters and affiliate Medical teams, across all therapeutic areas. Isma is very passionate about patient involvement in the Research & Development of innovative medicines, the life-cycle management of marketed products and is working extensively with various stakeholders to involve patients in the benefit-risk assessment of medicines.
Prior to her current role, Isma was responsible for advancing Amgen’s leadership in Global Patient Safety & Labeling. With over 20 years of industry experience, she has held various roles with increasing level of responsibility in different organizations. Prior to joining Amgen, she served as Vice President and Head of Safety Surveillance and Risk Management at Sanofi Genzyme. She has also worked in Clinical Development, Marketing, Medical Affairs and Executive Management at Eli Lilly France, Pfizer, and Wyeth Pharmaceuticals.
Isma Benattia received her medical degree from Faculte de Medecine d’Alger and Faculte de Medecine Pitie Salpetriere Paris, specializing in Psychiatry with a focus on the pharmacology of psychotropics. She also earned Master of Business Administration at the Massachusetts Institute of Technology Sloan School of Management, as well as Master in Bioethics from the University of Pennsylvania
Professor Bas Bloem is a consultant neurologist in the Department of Neurology, Radboud University Medical Center in the Netherlands. He received his MD degree (with honor) at Leiden University Medical Centre in 1993. In 1994, he obtained his PhD degree in Leiden, based on a thesis entitled “Postural reflexes in Parkinson’s disease.” He was trained as a neurologist between 1994-2000. He received additional training as movement disorders specialist during fellowships at The Parkinson’s Institute in Sunnyvale, California (with Dr. J.W. Langston) and at the Institute of Neurology, Queen Square, London (with Prof. N.P. Quinn and Prof. J.C. Rothwell).
In 2002, he founded and became medical director of the Parkinson Centre Nijmegen (ParC), which was recognized from 2005 onwards as a center of excellence for Parkinson’s disease. Together with Dr. Marten Munneke, he also developed ParkinsonNet, an innovative health care concept of professional networks for Parkinson’s patients covering all of the Netherlands (www.parkinsonnet.nl). In September 2008, he was appointed as professor of neurology, with movement disorders as a special area of interest.
Prof. Bloem has published over 650 publications, including over 500 peer-reviewed international papers. His H-index is 81 (Google Scholar).
Bora has partnered with medical affairs organizations to create impact and value for patients and healthcare providers globally. He is the leader of ZS’s medical affairs service line in Europe, which is part of the R&D excellence practice area. Bora is also a member of MAPS Digital Strategy Focus Area Working Group building awareness and understanding of digital opportunity and drive transformation with the broader medical affairs community.
Catrinel – VP, Head of Global Medical Affairs at UCB Biopharma – is a physician and senior pharmaceutical medicine leader passionate about delivering value for Patients and working for People.
Thriving at the intersection of science, drug development and patient care. Humbled and excited by innovation in healthcare and pharmaceutical business & new opportunities to better serve the patients (precision medicine, digital, health ecosystem solutions).
Catrinel has a track record in excellent leading of diverse teams and matrix projects; equally engaged in developing the strategy and architecture, and bringing them to life operationally. Experience and passion for international exposure in multicultural and interdisciplinary environments.
Along her 22 years’ experience in pharma industry she worked in diverse Medical Affairs roles – local, EU and global – covering team leadership lifecycle & portfolio strategy, pre-launch & launch, working with Pfizer and Amgen before her current role with UCB.